Results Of Pluristem Therapeutics (PSTI)'s Phase 1/2 Muscle Injury Trial To Be Announced On January 21, 2014
1/6/2014 9:23:44 AM
HAIFA, Israel, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), today announced that the results of the company's Phase I/II clinical trial testing the safety and efficacy of PLacental Expanded (PLX-PAD) cells for the treatment of muscle injury will be presented on January 21, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by